Latest Breaking News On - Arvind dasari - Page 2 : comparemela.com

Fruquintinib Provides Meaningful Benefit in Refractory Metastatic CRC

Fruquintinib Provides Meaningful Benefit in Refractory Metastatic CRC
keysnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from keysnews.com Daily Mail and Mail on Sunday newspapers.

United statesArvind dasariUniversity of texas md anderson cancer centerHealthday newsCancer center

Was the Fruquintinib Trial for Metastatic CRC a Win?

Despite the overall survival benefit associated with fruquintinib, weighing the risks and benefits of the drug remains important; and one oncologist questioned the trial s placebo arm.

United statesSan franciscoHong kongArvind dasariTemidayo fadeluAlan venookVinay prasadUniversity of californiaHarvard medical schoolMd anderson cancer centerDana farber cancer centerDrug administrationCancer centerMedscape medical newsColorectal cancerBiologic therapy

Fruquintinib improved survival in patients with refractory metastatic colorectal cancer

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer.

United statesArvind dasariDanielle ellisAmerican cancer societyUniversity of texas md anderson cancer centerEuropean society for medical oncologyEuropean unionDrug administrationCancer centerEuropean societyMedical oncologyPrincipal investigatorGastrointestinal medical oncologyManderson cancer

Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial, published today in The Lancet, were first presented at the European Society for Medical Oncology (ESMO) Congress 2022.

United statesArvind dasariAmerican cancer societyUniversity of texas md anderson cancer centerEuropean society for medical oncologyEuropean unionDrug administrationCancer centerEuropean societyMedical oncologyGastrointestinal medical

Patients with refractory metastatic colorecta

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial, published today in The Lancet, were first presented at the European Society for Medical Oncology (ESMO) Congress 2022.

United statesArvind dasariHutchison medipharmaUniversity of texas md anderson cancer centerDrug administrationAmerican cancer societyEuropean society for medical oncologyEuropean unionCancer centerEuropean societyMedical oncologyGastrointestinal medical